Added Cynapsus and Axovant pipeline & market cap along with a few of GC comments. Cynapsus sold for $624M with one drug/indication.


https://www.redchip.com/events/14/december-6-...rence/ambs

Single Asset CNS Story, Eltoprazine could become something like this down the road
http://www.acadia-pharm.com/pipeline/ Mkt cap: $3.57B
https://www.crunchbase.com/organization/acadi...aceuticals
Amount Raised at IPO: $35M Total Funding Amount $156M

Eltoprazine compares favorably to this compound
https://www.adamaspharma.com/pipeline/ Mkt cap: $799.084M
https://www.crunchbase.com/organization/adama...aceuticals
Amount Raised at IPO: $44M Total Funding Amount $82M

http://www.acorda.com/products/pipeline Mkt cap: $953.64M
https://www.crunchbase.com/ipo/acorda-therape...--08977ccb
Amount Raised at IPO: $33M

Parkinsons application is the lead for Eltoprazine with orphan designtion (2016) likey to get to market quickly. $2B+ annual market opportunity. Expand into Alzheimer disease where Eltoprazine compares very favorbly to Avanir's drug

http://www.avanir.com/science/pipeline Mkt cap: $3.5B Sold
https://www.crunchbase.com/organization/acadi...aceuticals
Amount Raised at IPO: $200M Total Funding Amount $46M

Japan’s Otsuka to buy U.S. drug maker Avanir for $3.5 billion
http://fortune.com/2014/12/02/japans-otsuka-t...5-billion/

Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutic for $624 million US
https://www.businesswire.com/news/home/201608...erapeutics
https://web.archive.org/web/20141204151940/ht....php?pid=7
https://www.crunchbase.com/organization/cynap...erapeutics
Amount Raised at IPO: $72M

Axovant Sciences Ltd. (AXON) Mkt cap: $570M (was $2B+ in June)
http://www.axovant.com/research-pipeline/our-pipeline/
https://www.crunchbase.com/organization/axovant-sciences
Amount Raised at IPO: $315M